AN2 Therapeutics and GSK Enter Tuberculosis Collaboration Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy GSK?
Collaboration Announcement: AN2 Therapeutics (ANTX) has entered into a collaboration agreement with GSK (GSK) to develop new therapies for tuberculosis.
Funding Support: The Gates Foundation will provide a third year of funding to support AN2's efforts within this collaboration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 54.510
Low
20.15
Averages
38.72
High
55.60
Current: 54.510
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GSK and Alfasigma Enter License Agreement for Linerixibat
- License Agreement: GSK has signed a licensing agreement with Alfasigma, granting Alfasigma worldwide exclusive rights to develop, manufacture, and commercialize linerixibat, an investigational ileal bile acid transporter inhibitor targeting cholestatic pruritus in primary biliary cholangitis, showcasing potential in the rare disease sector.
- Upfront and Milestone Payments: GSK will receive an upfront payment of $300 million, with an additional $100 million upon FDA approval, and $20 million upon EU and UK approval, along with up to $270 million in sales-based milestone payments, significantly enhancing GSK's cash flow.
- Royalty Earnings: GSK will earn tiered double-digit royalties on net sales worldwide from linerixibat, providing a stable revenue stream that supports the company's future financial performance.
- Drug Development Context: Linerixibat has received Orphan Drug Designation in the US, EU, and Japan, and priority review in China, indicating its significance in treating patients with primary biliary cholangitis and potentially opening new market opportunities for GSK.
See More
Trump's Comments Lead to Drop in Tylenol Prescriptions for Pregnant Women
- Prescription Decline: A study published in The Lancet reveals that after Trump linked Tylenol to autism, prescriptions for acetaminophen among pregnant women dropped by 10%, indicating a significant impact on public trust in medication safety.
- Maximum Decline: The study noted a peak decline of 20% in prescriptions during the third week post-September 22, suggesting that Trump's comments directly influenced pregnant women's medication choices, potentially leaving thousands without necessary pain or fever treatment.
- Emergency Visit Data: The findings are based on nearly 90,000 emergency department visits by pregnant women and approximately 853,000 by non-pregnant women, highlighting how fear stemming from public statements can adversely affect health management decisions.
- Medication Usage Shift: Concurrently, the study found a 71% increase in prescriptions for leucovorin among children, reflecting a possible over-reliance on alternative medications due to misconceptions stemming from Trump's remarks.
See More
CDC Urges Vaccination Amid Measles Outbreak
- Importance of Vaccination: Jay Bhattacharya, the director of the NIH, emphasized that there is no cure for measles, making prevention critical, and that the MMR vaccine is the most reliable method to protect individuals and entire communities.
- Current Outbreak Status: South Carolina is experiencing a measles outbreak with 985 reported cases, accounting for a majority of U.S. cases, while the CDC has recorded over 1,000 cases nationwide as of February 26, indicating the severity of the situation.
- Vaccine Market Dynamics: Merck and GSK market MMR vaccines in the U.S., and with the escalating outbreak, the demand for vaccines is likely to rise significantly, potentially impacting the sales performance of both companies.
- Public Health Advocacy: Bhattacharya released a video on social media urging the public to get vaccinated, highlighting that vaccination is not only crucial for individual health but also a key measure to protect communities from the outbreak.
See More
Funko Shares Surge 25% as Investor Urges Strategic Alternatives
- Stock Surge: Toymaker Funko's shares jumped approximately 25% following Pleasant Lake Partners' urging for the company to explore strategic alternatives, indicating strong market optimism and potential for new growth avenues.
- Strategic Restructuring: Werewolf Therapeutics has hired Piper Sandler to manage a sale process, highlighting the company's proactive approach to cut operating costs by 64% through layoffs, aiming to enhance financial stability amid restructuring efforts.
- Market Dynamics: The surge in Funko's stock price, coupled with strategic recommendations from its investors, may attract further investor interest, potentially boosting its market performance and overall valuation.
- Private Equity Opportunities: In the private equity space, David Altshuler from Cresta Fund Management discussed opportunities in the energy transition market, reflecting investor interest in the potential value of Funko and similar companies.
See More
ViiV's VH184 Phase 1 Data Shows Promising Long-Acting Potential
- Dosing Frequency: ViiV Healthcare's third-generation integrase strand transfer inhibitor VH184 shows potential for dosing as infrequently as twice a year, which could significantly improve patient adherence and reduce treatment burden.
- Drug Stability: One formulation of VH184 demonstrated steady drug levels through month seven, indicating its effectiveness and safety in long-term treatment, potentially offering better options for chronic disease patients.
- Resistance Profile Advantage: VH184 exhibited an enhanced resistance profile in vitro compared to Gilead's bictegravir, suggesting a competitive edge in antiviral therapy that may attract more clinical applications.
- Clinical Trial Results: ViiV's phase 2b trial revealed that 94% of individuals receiving intravenous lotivibart maintained viral suppression, showcasing the efficacy of this combination therapy and potentially advancing its application in HIV treatment.
See More
GSK Acquires 35Pharma for $950 Million
- Acquisition Deal: GSK plc has agreed to acquire Canada-based clinical-stage biopharmaceutical company 35Pharma for $950 million, aiming to enhance its competitive edge in novel protein therapeutics, particularly in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure (PH-HFpEF).
- Clinical Advancement: The acquisition includes HS235, an investigational drug that has completed phase 1 trials in healthy volunteers, with studies set to commence imminently for PAH, indicating significant market potential as the global pulmonary hypertension therapy market is projected to reach $18 billion by 2032.
- Market Outlook: HS235 targets the activin receptor signaling pathway, expected to capture 50% of the pulmonary hypertension treatment market, and its design enhances selectivity, reducing binding to ligands associated with adverse events, showcasing its differentiated clinical application.
- Licensing Agreement: GSK has also entered into a deal with Frontier Biotechnologies, which will receive $40 million upfront and up to $963 million in milestone payments, responsible for advancing two investigational assets, while GSK will handle subsequent global clinical development and commercialization activities.
See More
GSK and Alfasigma Enter License Agreement for Linerixibat
- License Agreement: GSK has signed a licensing agreement with Alfasigma, granting Alfasigma worldwide exclusive rights to develop, manufacture, and commercialize linerixibat, an investigational ileal bile acid transporter inhibitor targeting cholestatic pruritus in primary biliary cholangitis, showcasing potential in the rare disease sector.
- Upfront and Milestone Payments: GSK will receive an upfront payment of $300 million, with an additional $100 million upon FDA approval, and $20 million upon EU and UK approval, along with up to $270 million in sales-based milestone payments, significantly enhancing GSK's cash flow.
- Royalty Earnings: GSK will earn tiered double-digit royalties on net sales worldwide from linerixibat, providing a stable revenue stream that supports the company's future financial performance.
- Drug Development Context: Linerixibat has received Orphan Drug Designation in the US, EU, and Japan, and priority review in China, indicating its significance in treating patients with primary biliary cholangitis and potentially opening new market opportunities for GSK.
See More
Trump's Comments Lead to Drop in Tylenol Prescriptions for Pregnant Women
- Prescription Decline: A study published in The Lancet reveals that after Trump linked Tylenol to autism, prescriptions for acetaminophen among pregnant women dropped by 10%, indicating a significant impact on public trust in medication safety.
- Maximum Decline: The study noted a peak decline of 20% in prescriptions during the third week post-September 22, suggesting that Trump's comments directly influenced pregnant women's medication choices, potentially leaving thousands without necessary pain or fever treatment.
- Emergency Visit Data: The findings are based on nearly 90,000 emergency department visits by pregnant women and approximately 853,000 by non-pregnant women, highlighting how fear stemming from public statements can adversely affect health management decisions.
- Medication Usage Shift: Concurrently, the study found a 71% increase in prescriptions for leucovorin among children, reflecting a possible over-reliance on alternative medications due to misconceptions stemming from Trump's remarks.
See More
CDC Urges Vaccination Amid Measles Outbreak
- Importance of Vaccination: Jay Bhattacharya, the director of the NIH, emphasized that there is no cure for measles, making prevention critical, and that the MMR vaccine is the most reliable method to protect individuals and entire communities.
- Current Outbreak Status: South Carolina is experiencing a measles outbreak with 985 reported cases, accounting for a majority of U.S. cases, while the CDC has recorded over 1,000 cases nationwide as of February 26, indicating the severity of the situation.
- Vaccine Market Dynamics: Merck and GSK market MMR vaccines in the U.S., and with the escalating outbreak, the demand for vaccines is likely to rise significantly, potentially impacting the sales performance of both companies.
- Public Health Advocacy: Bhattacharya released a video on social media urging the public to get vaccinated, highlighting that vaccination is not only crucial for individual health but also a key measure to protect communities from the outbreak.
See More
Funko Shares Surge 25% as Investor Urges Strategic Alternatives
- Stock Surge: Toymaker Funko's shares jumped approximately 25% following Pleasant Lake Partners' urging for the company to explore strategic alternatives, indicating strong market optimism and potential for new growth avenues.
- Strategic Restructuring: Werewolf Therapeutics has hired Piper Sandler to manage a sale process, highlighting the company's proactive approach to cut operating costs by 64% through layoffs, aiming to enhance financial stability amid restructuring efforts.
- Market Dynamics: The surge in Funko's stock price, coupled with strategic recommendations from its investors, may attract further investor interest, potentially boosting its market performance and overall valuation.
- Private Equity Opportunities: In the private equity space, David Altshuler from Cresta Fund Management discussed opportunities in the energy transition market, reflecting investor interest in the potential value of Funko and similar companies.
See More
ViiV's VH184 Phase 1 Data Shows Promising Long-Acting Potential
- Dosing Frequency: ViiV Healthcare's third-generation integrase strand transfer inhibitor VH184 shows potential for dosing as infrequently as twice a year, which could significantly improve patient adherence and reduce treatment burden.
- Drug Stability: One formulation of VH184 demonstrated steady drug levels through month seven, indicating its effectiveness and safety in long-term treatment, potentially offering better options for chronic disease patients.
- Resistance Profile Advantage: VH184 exhibited an enhanced resistance profile in vitro compared to Gilead's bictegravir, suggesting a competitive edge in antiviral therapy that may attract more clinical applications.
- Clinical Trial Results: ViiV's phase 2b trial revealed that 94% of individuals receiving intravenous lotivibart maintained viral suppression, showcasing the efficacy of this combination therapy and potentially advancing its application in HIV treatment.
See More
GSK Acquires 35Pharma for $950 Million
- Acquisition Deal: GSK plc has agreed to acquire Canada-based clinical-stage biopharmaceutical company 35Pharma for $950 million, aiming to enhance its competitive edge in novel protein therapeutics, particularly in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure (PH-HFpEF).
- Clinical Advancement: The acquisition includes HS235, an investigational drug that has completed phase 1 trials in healthy volunteers, with studies set to commence imminently for PAH, indicating significant market potential as the global pulmonary hypertension therapy market is projected to reach $18 billion by 2032.
- Market Outlook: HS235 targets the activin receptor signaling pathway, expected to capture 50% of the pulmonary hypertension treatment market, and its design enhances selectivity, reducing binding to ligands associated with adverse events, showcasing its differentiated clinical application.
- Licensing Agreement: GSK has also entered into a deal with Frontier Biotechnologies, which will receive $40 million upfront and up to $963 million in milestone payments, responsible for advancing two investigational assets, while GSK will handle subsequent global clinical development and commercialization activities.
See More
